2. Phillips K, Ansell J. The Outpatient Management of Oral Vitamin K Antagonist Therapy: Defining and Measuring High Quality Manage- ment. Exp Rev Cardiovas Therap. 2008;6:57-70. 3. Ansell JE. Optimizing the Efficacy and Safety of Oral Anticoagulant Therapy: High Quality Dose Management, ...
This makes the test specific for the vitamin K-dependent factors II, VII and X and independent of the level of fibrinogen and factor V in the patient plasma. The use of a single species thromboplastin makes it easier to standardize the assay. The Owren type PT assay has several advantages ...
(PTLab/INRLab = 43 s/4.3). The delay in the rise of G for the patient on Coumadin therapy can be explained by the delay in the conversion of fibrinogen to fibrin, as it is well known that Coumadin inhibits the synthesis of the active form of vitamin K dependent pro-coagulation...